GB Group Ord Shs GBGPF

GB Group plc is a United Kingdom-based company, which provides identity data intelligence products and services helping organizations recognize and verify all elements of an individual's identity at key interactions in their business processes. The Company's segments include location, identity and fraud. The location segment includes address lookup, verification and capture; e-mail validation; phone verification, and data maintenance services. The identity segment includes document verification, data verification and identity investigation services. Its identity verification solutions can be configured to carry out a wide range of functions, including know your customer checks, anti-money laundering checks, age verification checks and liveness detection. The fraud segment includes transaction fraud monitoring, combating origination fraud and in-life fraud investigation services. It provides artificial intelligence powered screening for automatic onboarding or referral of customers.

OTCPK:GBGPF - Post by User

GB Group Ord Shs

<< Previous

Bullboard Posts

Next >>

Post by The6Kidon Jan 21, 2017 3:21pm

216 Views

Post# 25737635

Altacorp Analyst coverage - Great-West Life insurance

Here's a portion of the report released Jan 18, 2017. Not sure how if PDF's can be posted here.

Highlights from AltaCorp/ATB Conference: We hosted CMED at our 5th Annual Institutional Investors Conference where CEO Brent Zettl presented to a near capacity crowd. Management outlined that within one year of product launch, medical cannabis oils now represent 40% of CMED’s total sales. In our opinion, the direction of CMED sales is continued growth in medical cannabis oil sales, and the soon to be released gel caps (which are more conducive for the pharmaceutical market.) On the international front, CMED is holding discussions with parties that represent seven different countries which are in various stages of formulating medical cannabis legislation. CMED is looking to leverage its experience and competitive advantage of being the “best in class” medical cannabis producer in order to tap the considerable international market opportunities. Management estimates that medical cannabis could help reduce pain management related claim costs by 50-80%, providing insurance companies a critical incentive for prescription approvals. Increasing acceptance of medial cannabis by insurance providers could serve as a major tailwind for the burgeoning industry. CMED noted that Great-West Life, a Canadian insurer, is currently running a medical cannabis test program with the Company.

Transferring Coverage with an Outperform rating and $20.00 price target: We view CMED as an industry leader in the medical cannabis market which is witnessing a more favourable regulatory environment coupled with accelerating acceptance within the medical community, particularly with respect to chronic pain management. We believe CMED has an excellent opportunity to grow sales and profitability alongside the growing global acceptance of medical cannabis; the pain management market in Canada is estimated by management to be $6 billion. We transfer coverage of CMED shares with an Outperform rating and a $20.00 per share 12-month target. We value the Company at 11x EV/EBITDA against our FY2019 estimates, consistent with peer group valuations. Pending catalysts for the stock include; continued sales growth, profitability, the achievement of GMP compliance for medical cannabis oils, the launch of medical cannabis gel caps and the completion of the Company’s CAPRI clinical trial, all expected in 2017.